The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH MPN 2026 | What evidence led to the FDA accepted NDA for rusfertide in PV?
Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, FL, details the evidence that led to the recently accepted NDA and priority review for rusfertide in the treatment of polycythemia vera (PV). Dr Kuykendall outlines favorable outcomes following the Phase II REVIVE (NCT04057040) trial, the follow-up THRIVE (NCT06033586) study, and the Phase III VERIFY (NCT05210790) study, which confirmed the efficacy of rusfertide versus placebo in reducing the requirement for phlebotomies in patients. This interview took place at the ESH 11th Translational Research Conference on Myeloproliferative Neoplasms (ESH MPN 2026) in Estoril, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
